RATIONALE: Air pollution particles of 2.5 mm (PM 2.5 ), besides causing respiratory and cardiovascular disease, facilitate allergen absorption and exacerbate nasal allergy. Powdered hydroxyl-propyl-methyl-cellulose (pHPMC), insufflated nasally, swells and forms a gel barrier against offending allergens. This in vitro study examined the ability of pHPMC to adsorb PM 2.5. METHODS: Squares of 1.5% agar (1 cm 2 ) were mounted on microscope slides.Gels of pHPMC and lactose (control) were prepared by mixing 0.25g of powder with 5ml saline to obtain the desired viscosity of gel. A thin;50ml layer of pHPMC, lactose or vehicle (no product control) was applied to each slide. Fluorescent particles (30ml,1.7-2.2 mm) were applied adjacent to the test substance. Slides were incubated at 358C and 90% relative humidity to stimulate nasal for conditions for 15, 30, 60, 180 and 360 minutes after which agar blocks were removed, the pHPMC removed by washing and PM 2.5 absorbed into the agar extracted and counted by flow cytometry. RESULTS: With lactose and no product, the number of particles absorbed into the agar increased slowly with time to maxima of 12,989 6 1137 and 12,999 6 465 (mean6SEM) at 360 min. With pHPMC only 826 6 312 particles were recovered showing that pHPMC adsorbed PM 2.5 not allowing uptake into the agar. CONCLUSIONS: pHPMC adsorbed PM 2.5 reducing their uptake into agar by 94% indicating it will have a potent ability, when insufflated into the nose, to protect the nasal mucosa from damage by PM 2.5 .
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Comparison between PM2.5 levels on east coast and state of California in relationship to asthma Ariel J. Stateman, MS, Hayat H. Srour, MS, Joshua K. Baguley, MS, Shandra V. Bellinger, MS, and Felix E. Rivera-Mariani, PhD; College of Biomedical Sciences, Larkin University, Miami, FL. RATIONALE: Asthma is a chronic disease that causes swelling of the airways making it difficult to breathe. Common triggers that cause inflammation in the airway include pollen, smoke, stress, chemicals, and extreme weather changes, which may contribute to asthma. There is limited research that explains why California, despite many wildfires, has a lower prevalence of asthma compared to the east coast. METHODS: Data on asthma prevalence, by state, for the year 2015 were obtained from Adults Asthma data collected via the Behavioral Risk Factor Surveillance System of the US Center for Disease Control and Prevention (CDC). PM2.5 concentrations for the year 2015 were retrieved from the publicly-available data from the Air Quality Index Report of the US Environmental Protection. RESULTS: For the year 2015, the highest prevalence of asthma was among the east coast (all states that have shorelines on the Atlantic Ocean) with 9.2% of adults. Despite California being in the top two states for wildfires, it has one of the lowest prevalence asthma (7.7%) nationwide. When looking at the number of days PM2.5 was the main pollutant across each state, California had a 19% less days (128.2 days) than the east coast states (153.4 days). CONCLUSIONS: Different rates of asthma between different regions within the US may be due to different exposure risk to PM2.5 that originate from sources other than natural disasters, such as forest fires. Future studies should focus on other regions with regards to high PM2.5 levels in relationship to asthma.
Practice Patterns of Chemotherapy Skin Testing and Desensitization
Amy Levin, MD, and Aleena Banerji, MD; Massachusetts General Hospital, Boston, MA. RATIONALE: Hypersensitivity reactions (HSRs) to chemotherapeutic agents are common and limit treatment options when skin testing and desensitization protocols are not utilized. We performed a survey to evaluate national practice patterns. METHODS: We sent an 8-question survey through the American Academy of Allergy, Asthma & Immunology (AAAAI) to allergy/immunology physician members actively in practice. Surveys were sent to a 20% representative sample. We obtained basic characteristics including gender, practice type, practice location, and year of fellowship graduation. Frequency of and barriers to chemotherapy skin testing and desensitization were assessed. RESULTS: Among 806 physicians who received the survey, 75 participated (response rate 9%). Seventy-two of the respondents met criteria for inclusion (three respondents not in active practice). Over half of respondents were male (41/72; 57%), completed training after 2000 (40/70; 57%), and practiced in a non-academic group setting (34/67; 51%). Few allergists performed chemotherapy skin testing (13/72; 18%) or desensitization (17/ 71; 24%). The most common barriers to chemotherapy desensitization included: lack of appropriate patient population (64%), lack of access to chemotherapy (43%), time (30%), cost (28%), personnel (28%), and lack of access to desensitization protocols (28%). Most respondents (51/71; 72%) were interested in learning about these protocols. CONCLUSIONS: Allergists/immunologists infrequently skin test and desensitize to chemotherapeutic agents but are interested in learning more. They perform these two procedures at comparable rates, despite the greater ease and fewer resources required for skin testing. Expanded education efforts around chemotherapy skin testing and desensitization are important for expanding the scope of allergy practice and improving care.
Characteristics of Persistent Penicillin Allergy Labels in a Large Electronic Health Record Database
Cosby A. Stone, Jr, MD, MPH, Wei-Qi Wei, and Elizabeth J. Phillips, MD FAAAAI FIDSA; Vanderbilt University Medical Center, Nashville, TN. RATIONALE: Penicillin allergy labels are prevalent, and associated with inferior individual and public health outcomes. Most penicillin allergy histories are either low risk or inaccurate: >96% of patients reporting penicillin allergy are negative on formal testing. To better target specific populations for penicillin allergy de-labeling we aimed to define characteristics of patients persistently labeled as penicillin allergic. METHODS: From the Vanderbilt Synthetic Derivative (n52,993,336) we identified persons reporting penicillin-class allergies and stratified by age, sex, race, and linkage to Vanderbilt outpatient primary care. We examined risk factors for patients who were persistently labeled versus those who had their labels successfully removed. RESULTS: Of 2,993,336 patients studied, 237,144 (7.9%) had carried a penicillin allergy label at some point in their care. The proportion of penicillin allergy label carriage was significantly higher over the age of 50 (9.2%) versus under 50 (6.8%), in women (9.7%) versus men (6.8%), European-(10.3%) versus African-(6.5%) Americans, and those whose medical home was at Vanderbilt (14.3%) versus not (6.8%) (all p-values <0.0005, two-sided test of proportions). For patients ever labeled as penicillin allergic, 86,220 (36.4%) had received a penicillin-class drug, yet only 31,700 (36.7%) or 13.3% overall were effectively de-labeled. Delabeling was less common among age 18-50, men, European-Americans, and those whose medical home was not at Vanderbilt (all p-values <0.0005,chi-square test). CONCLUSIONS: Despite prevalent penicillin exposure in patients labeled as penicillin allergic, penicillin allergy labels are frequently persistent and associated with age, sex and ethnicity. Both targeted and generalizable strategies for effective penicillin allergy label removal are needed.
